Sanofi Pasteur, the vaccines division of Sanofi, announced that its tetravalent dengue vaccine candidate demonstrated proof of efficacy against dengue, a threat to almost 3 billion people, in the world's first ever dengue efficacy trial conducted in Thailand, with excellent safety.
Sanofi Pasteur's dengue vaccine demonstrates proof of efficacy